002737.SZ
Sunflower Pharmaceutical Group Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 12.86
−1.38%Sep 18, 2026, 07:48 UTC
Sunflower Pharmaceutical used 400 million yuan of idle self-owned funds to purchase fixed-income non-principal-protected floating-return wealth management products, involving products from China Merchants Bank, Industrial Bank, Shanghai Pudong Development Bank, and China CITIC Bank.
Source:Aug 28, 2026, 08:00 UTC
Kuihua Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 79.4695 million yuan, down 2.26% year-on-year, with revenue of 1.498 billion yuan, up 14.34%.
Source:Aug 21, 2026, 08:19 UTC
Sunflower Pharmaceutical's controlling subsidiary Sunflower Pharmaceutical Group (Hengshui) Defier Co., Ltd. received a drug registration certificate from the National Medical Products Administration for glucosamine sulfate capsules, enriching the company's rheumatism and bone disease product pipeline.
Source:Aug 7, 2026, 07:45 UTC
Kuihua Pharmaceutical used 500 million yuan of idle funds to purchase wealth management products, including 200 million yuan for China Merchants Bank's Juyishengjin Series Company (35-day) B wealth management plan and 300 million yuan for CIB Wealth Management's Anyingxiang Fixed Income Steady Two-Month Holding Period No. 47 wealth management product.
Source: